Prenetics Global reports Q3 results

Prenetics Global reported a Q3 net loss of $25.4M but revenue grew 171.6% year-over-year to $64.1M, exceeding estimates by $0.89M. The company's cash and current financial assets increased to $111.5M by September 30, 2026, up from $109.4M three months earlier.

Original reporting
Published Nov 18, 2026, 1:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prenetics Global reports Q3 results — source image
Decision brief

The 30-second read

$PRENeutralMed
01

Why it matters

Traders can update near-term expectations for growth versus profitability and reassess balance-sheet runway using the reported cash level.

02

Market read

A fresh quarterly print with revenue beat and cash balance provides a decision point for PRE positioning, despite limited detail on guidance or profitability drivers.

03

What to watch

Without margin, cash burn rate, guidance, or customer/contract details, traders may overreact to the headline net loss or the Y/Y revenue surge.

Relevance 8/10Novelty 8/10Timing: as-of the Q3 results release date (published 2026-11-18)

Background

The piece is a brief earnings release summary for Prenetics Global’s Q3 results.

Company-level read

Ticker impact

$PRENeutralMedium confidence
Context

Prenetics Global reported Q3 results with a $25.4M net loss and $64.1M revenue up 171.6% Y/Y, a direct earnings datapoint for PRE.

Expected impact

Likely mixed reaction, with upside bias from the large Y/Y revenue growth offset by concern over the sizable net loss.

Evidence & confidence

The article provides only headline financials (net loss, revenue beat, cash level) without guidance or segment detail, limiting conviction on direction and magnitude.

Market effects

May influence sentiment toward diagnostics/healthtech service providers by reinforcing that top-line growth can coexist with losses.

No clear regional spillover indicated beyond the issuer’s own financials.

Limited, as the article contains no cross-border policy, supply-chain, or macro catalyst.

Counterpoint

The revenue beat and cash increase could be masking deteriorating unit economics, so the net loss may dominate the tape.

Key entities

  • Prenetics Global

    Reported Q3 net loss, revenue growth, and cash/current financial assets as of Sept. 30, 2026.

Related articles

$PREMed

Prenetics Global Ltd (PRE): Financial results for FY2027

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven

$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

$PREHighAI 9/10

Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.